Trials / Completed
CompletedNCT02191761
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Phase1, Open-Label, Dose Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Biosplice Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SM04755 administered orally. Upon determination of the maximum tolerated dose (MTD), expansion cohorts may be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SM04755 | Escalating Doses |
Timeline
- Start date
- 2014-06-19
- Primary completion
- 2015-05-20
- Completion
- 2015-05-20
- First posted
- 2014-07-16
- Last updated
- 2018-09-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02191761. Inclusion in this directory is not an endorsement.